McGee M G, Myers T J, Abou-Awdi N, Dasse K A, Radovancevic B, Lonquist J L, Duncan J M, Frazier O H
Cullen Cardiovascular Research Laboratories, Texas Heart Institute, Houston 77225-0345.
ASAIO Trans. 1991 Jul-Sep;37(3):M425-6.
The Heartmate-1000IP, an intracorporeal, pneumatically activated, pulsatile left ventricular assist device (LVAD) with textured blood-contacting surfaces, is undergoing clinical evaluation as a bridge to heart transplantation (HTx). During a 3 year period (January 1988 to April 1991), the authors evaluated 12 patients who required extended LVAD support (greater than 30 days) while awaiting HTx. Duration of support ranged from 31 to 233 days (mean, 117 days). LVAD performance was excellent, with average pump flow indices of 2.5-3.5 L/min/m2. Long-term antithrombotic therapy consisted of dipyridamole and aspirin in all except one patient who received only low-molecular-weight dextran. After the initial recovery period, prothrombin and partial thromboplastin times returned to baseline levels. Plasma-free hemoglobin levels averaged less than 10 mg/dl. One patient is currently receiving support (91+ days); the 11 other patients underwent successful HTx, with follow-up ranging from 7 to 36 months. The authors' cumulative experience with this LVAD totals more than 1,506 days of support (greater than 4 years) without evidence of any thromboembolic episodes. These results suggest that this LVAD provides an effective bridge to HTx for extended periods.
Heartmate - 1000IP是一种体内植入、气动驱动、搏动式左心室辅助装置（LVAD），其血液接触表面有纹理，目前正在作为心脏移植（HTx）的过渡治疗手段进行临床评估。在1988年1月至1991年4月的3年期间，作者评估了12例在等待心脏移植期间需要长期LVAD支持（超过30天）的患者。支持时间从31天到233天不等（平均117天）。LVAD性能出色，平均泵流量指数为2.5 - 3.5 L/min/m²。除1例仅接受低分子右旋糖酐治疗的患者外，所有患者的长期抗血栓治疗均采用双嘧达莫和阿司匹林。在初始恢复期后，凝血酶原时间和部分凝血活酶时间恢复到基线水平。血浆游离血红蛋白水平平均低于10 mg/dl。1例患者目前仍在接受支持治疗（91 +天）；其他11例患者成功接受了心脏移植，随访时间为7至36个月。作者使用该LVAD的累计经验总计超过1506天的支持时间（超过4年），且无任何血栓栓塞事件的证据。这些结果表明，这种LVAD能在较长时间内为心脏移植提供有效的过渡治疗。
